Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Illumina, Inc. (ILMN) CEO Francis deSouza Presents at J.P. Morgan 39th Annual Healthcare Conference (Transcript)

Illumina CEO Says Business Is Bouncing Back

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) is transforming genomic data bottlenecks into catalysts with the launch of Illumina Connected Analytics (ICA). This new and integrated bioinformatics solution provides a comprehensive, private, cloud-based data platform that empowers customers to manage, analyze, and explore large volumes of multi-omic data in a secure, scalable, and flexible environment. “Illumina Connected Analytics has appeared at a critical time for our research grou

New Bioinformatics Solution Powers Multi-Omics Discovery at Massive Scale

SAN DIEGO--(BUSINESS WIRE)--With genetic sequencing at the forefront of precision medicine, Illumina (NASDAQ: ILMN) is pleased to announce a portfolio of new and expanded oncology partnerships that further the company's commitment to develop standardized, globally distributable tools for precision oncology. Speaking today at the 39th Annual J.P. Morgan Healthcare Conference in San Francisco, California, Illumina CEO, Francis deSouza, announced a series of oncology partnerships that aim to expan

Illumina Announces New and Expanded Oncology Partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to Advance Comprehensive Genomic Profiling

Illumina (ILMN) collaborates with Helix with support from the CDC to set up an enhanced surveillance infrastructure to track the emergence and prevalence of B.1.1.7.

Illumina (ILMN), Helix Partner to Develop Tracking Setup in U.S.

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (Nasdaq: ILMN) and Helix today announced a collaboration to augment national surveillance infrastructure in the US to track the emergence and prevalence of novel strains of SARS-CoV-2 with support from the CDC. The combination of Illumina's sequencing technology and expertise and Helix's national COVID-19 testing footprint will significantly expand the country's existing surveillance efforts to detect and characterize emerging variants of SARS-CoV-2. T

Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US and Develop National Surveillance Infrastructure

iShares Nasdaq Biotechnology ETF

Moderna

Due to lucrative risk/reward setups and heightened fundamental demand, many active traders will be watching biotech stocks.

Active Traders Look to Biotech for 2021

The shares of Illumina Inc. (NASDAQ:ILMN) are up 3.2% at $374.30 at last check, after the biotechnology concern received an upgrade from Piper Sandler to "overweight" from "neutral," as well as a price-target hike to $415 from $340.

Biotech Stock Rises on Lofty Piper Sandler Bull Note

Alexandria Real Estate Equities

Cerner

Intuitive Surgical

Pfizer

Teladoc

Zoetis

True, there are political risks in the industry. But there are also lots of growth opportunities for investors in healthcare stocks.

7 Healthcare Stocks to Buy With the Sector Under Scrutiny

Microsoft

Palantir Technologies

SAP SE

Splunk

Salesforce

These big data stocks are the needle-movers of the industry and will leverage big data to make our lives easier and much more informed. The post 7 Big Data Stocks That Are Feeding Our Information Addiction appeared first on InvestorPlace.

7 Big Data Stocks That Are Feeding Our Information Addiction

Illumina (ILMN) signs agreement to expand the availability of WGS to enable faster and cost-effective diagnosis of genetic diseases in children.

Illumina (ILMN)-Harvard Pilgrim Partner to Expand WGS Access

SAN DIEGO & WELLESLEY, Mass.--(BUSINESS WIRE)--Illumina and Harvard Pilgrim Health Care expand access to whole-genome sequencing for genetic disease testing.

Illumina and Harvard Pilgrim Health Care Expand Access to Whole-Genome Sequencing for Genetic Disease Testing

Illumina, Inc. (ILMN) Presents at Piper Sandler Healthcare Broker Conference Call - (Transcript)

ST. LOUIS--(BUSINESS WIRE)--Additional Illumina assays to be combined with the PierianDx platform to reduce time, cost, and complexity of genomic reporting

PierianDx Announces Expanded Partnership with Illumina to Support Cancer Genomic Reporting in Global Markets

Illumina, best known for its genetic variation and biological function systems, trades at about 12x trailing Revenues, compared to over 19x for Intuitive Surgical, which manufactures robotic surgical platforms. Does this gap in Illumina's valuation make sense?

Illumina Looks Like Great Value Compared To Intuitive Surgical Stock

SAN DIEGO--(BUSINESS WIRE)---- $ILMN #ILMN--Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conference and invited investors to participate via webcast. Piper Sandler Annual Healthcare Conference Thursday, December 3, 2020 at 1:30pm Eastern Time The live webcast can be accessed in the Investor Info section of Illumina's web site under the "company" tab at www.illumina.com. A replay of the presentation will be posted on Illumina's website as soon as po

Illumina to Webcast Upcoming Investor Conference Presentation

Exact Sciences

Guardant Health Inc

Natera

Personalis Inc

Multiple companies are working on next-gen blood biopsies tech to detect cancer. The potential market size is big according to most estimates and analysts.

Liquid Biopsy Cancer Testing Is The Next Big Investment Opportunity

Liquid biopsy technology offers promise of the medical Holy Grail, early detection of multiple cancers. Illumina, Exact Sciences deals heating up a game-changing field in cancer treatment.

Wild Ride For Illumina Stock Shows Promise, Challenge Of Multi-Cancer Blood Tests

SAN DIEGO--(BUSINESS WIRE)--. Illumina, Inc. (NASDAQ: ILMN) is further extending the reach of the NextSeq™ 2000 Sequencing System with the commercial availability of the P3 high-output flow cell. The P3 flow cell offers 1.1 billion reads in a single sequencing run, almost three times more than previously available on Illumina's mid-throughput NextSeq sequencing portfolio, expanding the range of applications that run on the system. “The advanced yet affordable P3 flow cell for the NextSeq 2000 g

Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit

Twist Bioscience Corp

Western Digital

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DNA--Twist Bioscience Corporation (NASDAQ: TWST), Illumina, Inc. (NASDAQ: ILMN) and Western Digital (NASDAQ: WDC) today announced the formation of an alliance with Microsoft to advance the field of DNA data storage. These founding companies, alongside member organizations, will work together to create a comprehensive industry roadmap that will help the industry achieve interoperability between solutions and help establish the foundations for a cost-effec

Twist Bioscience, Illumina and Western Digital Form Alliance with Microsoft to Advance Data Storage in DNA

Illumina (ILMN) exhibits dismal segmental performance in the third quarter of 2020 due to pandemic-led business disruptions.

Illumina (ILMN) Q3 Earnings Top Estimates, Margins Decline

The genomic-sequencing leader is recovering more quickly from the COVID-19 pandemic than it anticipated.

Why Illumina's Q3 Results Were Better Than They Might Seem

Illumina Inc. (ILMN) CEO Francis deSouza on Q3 2020 Results - Earnings Call Transcript

Illumina (ILMN) delivered earnings and revenue surprises of 32.47% and 10.15%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Illumina (ILMN) Q3 Earnings and Revenues Surpass Estimates

Shares of Illumina (NASDAQ:ILMN) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 47.15% over the past year to $1.02, which beat the estimate of $0.77.

News for Illumina Stock (ILMN)